Application of eleutheroside B in preparation of medicine for preventing or treating acute kidney injury

A technology for acute kidney injury and Acanthopanax senticosus, applied in the field of biomedicine, can solve problems such as unreported effects, and achieve the effects of reducing apoptosis and necrosis response, reducing inflammatory response, and reducing the level of inflammatory factors

Inactive Publication Date: 2019-04-12
ANHUI MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, its use as a drug for the treatment of acute kidney injury has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of eleutheroside B in preparation of medicine for preventing or treating acute kidney injury
  • Application of eleutheroside B in preparation of medicine for preventing or treating acute kidney injury
  • Application of eleutheroside B in preparation of medicine for preventing or treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Protective effect of eleuthelis B (EB) on cisplatin (Cisplatin)-induced renal tubular epithelial cell injury in vitro.

[0036] MTT method: human renal tubular epithelial cells (HK2) cells were seeded in a 96-well plate at a seeding density of about 4000 cells / well. Cultured for 24 hours, after being starved for 12 hours with serum-free medium, they were divided into 8 groups, namely control group, cisplatin stimulation group and 8 eleutheroside B gradient dose groups (cisplatin stimulation + EB). 20 μM cisplatin was added to the group, and 20 μM cisplatin + 4 μM EB, 20 μM cisplatin + 8 μM EB, 20 μM cisplatin + 16 μM EB, 20 μM cisplatin + 32 μM EB, 20 μM cisplatin were added in the 8 eleutheroside B gradient dose groups. Platinum + 64 μM EB, 20 μM cisplatin + 128 μM EB, 20 μM cisplatin + 256 μM EB, 20 μM cisplatin + 512 μM EB, and continue to culture for 24 hours. After the incubation, 20 μL of 5 g·L-1 MTT solution was added to each well, and the incubation was continu...

Embodiment 2

[0042] The inhibitory effect of eleuthelis B on cisplatin-induced renal tubular epithelial cell inflammatory factors (TNF-α and IL-6) in vitro.

[0043] HK2 cells were seeded in 12-well plates at a seeding density of about 0.5×105 cells / well, and were divided into control group, cisplatin stimulation group, eleutheroside B group (EB) and cisplatin stimulation + EB group, Repeat the experiment 3-4 times for each group, incubate for 24 hours and starve for 12 hours with serum-free medium, then add 20 μM cisplatin in the model group, add eleutheroside B group (EB) and cisplatin + EB group respectively 128 μM eleutheroside B, continued to culture for 24 hours, washed three times with PBS, collected cells, extracted RNA, reverse transcribed, and amplified. Then Real time PCR was carried out to detect the expression levels of tumor necrosis factor (TNF-α) and interleukin-6 (IL-6), and the results were as follows: Figure 4 (TNF-α) and Figure 5 (IL-6).

[0044] Obtainable by this...

Embodiment 3

[0047]In vitro, eleuthelis B can inhibit the apoptosis and necrosis of renal tubular epithelial cells induced by cisplatin.

[0048] Western Blot: HK2 cells in the logarithmic growth phase were inoculated into 6-well plates at a seeding density of about 1.0×105 cells / ml, and were divided into control group, cisplatin stimulation group, and eleutheroside B group (EB) , cisplatin stimulation + eleutheroside B group (cisplatin stimulation + EB), add 20 μM cisplatin in the cisplatin stimulation group, add 20μM Cisplatin+128μM EB, repeat the experiment 3-4 times for each group, continue to culture for 24 hours, wash three times with PBS, collect the cells, extract the total protein, detect the changes in the expression levels of apoptosis-related proteins RIPK1 and RIPK3 by Western Blot, and Semi-quantitative analysis of RIPK1 and RIPK3 (eg Figure 6 and Figure 7 shown).

[0049] Obtainable by this embodiment:

[0050] Figure 6 and 7 The results of Western Blot and semi-qua...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of eleutheroside B in the preparation of a medicine for preventing or treating acute kidney injury. The present invention discloses the application of eleutheroside B as a medicine for treating acute kidney injury the first time. The eleutheroside B has a protective effect on cisplatin-induced renal tubular epithelial cell injury, has an inhibition effect oncisplatin-induced renal tubular epithelial inflammatory factors, reduces the levels of serum creatinine and blood urea nitrogen in a cisplatin-induced acute kidney injury model, has an inhibition effect on inflammation in the cisplatin-induced acute kidney injury model, and has an inhibition effect on apoptosis necrosis in the cisplatin-induced acute kidney injury model. The eleutheroside B effectively reduces the inflammatory reaction and apoptosis reaction caused by acute kidney injury, and then exerts the protective effect on the kidney. The eleutheroside B can effectively alleviate acute kidney injury and protect renal functions, and the action mechanism is associated with that the eleutheroside B reduces inflammatory factor level and lowers apoptotic necrosis. The eleutheroside B hasbroad application prospects, and provides more drug options for the treatment of acute kidney injury.

Description

technical field [0001] The invention relates to a biomedical technology, in particular to the application of Eleutheroside B (Eleutheroside B) in the preparation of medicines for preventing or treating acute kidney injury. Background technique [0002] Acute kidney injury (Acute Kidney Injury, AKI) is a common clinical critical disease, which can lead to incomplete repair of the kidney, persistent chronic inflammation and progressive fibrosis, and is an important cause of secondary chronic kidney disease, renal failure and death in hospitalized patients . So far, there is no effective treatment for AKI. Therefore, it is of great significance to find renoprotective drugs that can reduce tissue damage, promote repair, and prevent chronic fibrosis. [0003] Eleutheroside B (Eleutheroside B, EB), also known as syringin, has a molecular formula of C17H24O9, and its chemical structure is as follows: [0004] [0005] Eleutheroside B is the dried rhizome or stem of Acanthopana...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61P13/12
CPCA61K31/7034A61P13/12
Inventor 孟晓明杨琴李俊解雪峰臧洪梅李增张义龙黄成徐涛
Owner ANHUI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap